Plasmocin™ is a new generation of bactericidal antibiotic solution strongly active on Mycoplasma infected cells. Plasmocin™ contains two newly developed bactericidal components: one acts on bacterial protein synthesis by interfering with ribosome translation, and the other acts on bacterial DNA replication by interfering with the replication fork. These two specific and separate targets are found in all bacteria including mycoplasmas and are completely absent in eukaryotic cells.

Plasmocin™ is active both on extracellular mycoplasmas, cell associated mycoplasmas, as well as intracellular forms found in some specialized mammalian cells. The two constituent antibiotics of Plasmocin are actively transported into mammalian cells providing a synergistic killing effect on intracellular mycoplasmas without any apparent adverse effect on cellular metabolism. Thus after being treated with Plasmocin, a cell culture is not re-infected by mycoplasmas released from the intracellular compartments of infected cells following antibiotic removal.

Because of its mechanism of action, Plasmocin™ is also active on a broad range of extracellular and/or potentially intracellular Gram+ and Gram- bacteria.